Call for Basic Science Submissions: Translational Preclinical Models of IBD
Inflammatory Bowel Diseases® supports the mission of the Crohn's & Colitis Foundation by bringing the most impactful and cutting-edge clinical topics and research findings related to inflammatory bowel diseases (IBD) to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.
SCOPE: The Journal invites technical reviews or original research articles that add to the body of knowledge of the current status of in vivo, ex vivo, in silico, and humanized preclinical models of Crohn’s disease and ulcerative colitis. In this call for submissions, we are specifically interested in original manuscripts that report on the strategic use of existing or novel pre-clinical models of IBD to answer questions that advance our understanding of the pathogenesis of IBD as experienced by patients. In addition, articles that evaluate the translational value and positioning of different models to support the development of therapeutics for both Crohn’s disease and ulcerative colitis, are also encouraged. These papers will add to the understanding of Preclinical Human IBD Mechanisms as described in the Foundation’s Challenges in IBD document.
Areas of interest include but are not restricted to:
-
Animal models of chronic colitis and ileitis including genetically and immunologically manipulated mouse models and spontaneous models. Experimental studies comparing the utility of using 2 or more relevant in vivo models of chronic intestinal inflammation are particularly welcome.
-
Humanized animal models including but not restricted to human microbiota transplantation and T cell transfer models.
-
Animal models for important clinical manifestations of IBD, such as fistulas, strictures, chronic pain, extraintestinal manifestations or treatment-refractory inflammation.
-
Human ex-vivo models derived from patient samples, including but not limited to, intestinal organoids/iPSCs cells, gut-on-a-chip and 3-D systems, to investigate pathogenic mechanisms, validate research findings and development of personalized therapeutics in support of precision medicine solutions.
-
In silico models to understand disease mechanisms, mechanisms of action of novel drug targets and prediction of safety and efficacy new therapeutic candidates.
Papers should be prepared in compliance with the journal's Instructions for Authors and submitted through the Editorial Manger submission portal.
Submission as part of this call for papers is not a guarantee of acceptance. All submissions will undergo rigorous peer review. Please indicate in the cover letter accompanying your manuscript that you are submitting in reference to this call for papers.
If there are any questions, please contact Fabio Cominelli, Editor-in-Chief for Inflammatory Bowel Diseases®.
Deadline: 31 December 2023
